Mesenchymal Stem Cells News and Research

RSS

Stem-cell therapy holds promise for postinjury arthritis prevention

A novel stem-cell treatment may hold the key to treating osteoarthritis triggered by joint injury, suggest results from an animal study.

21 Aug 2012

Promising stem cell therapy may prevent osteoarthritis after joint injury

Duke researchers may have found a promising stem cell therapy for preventing osteoarthritis after a joint injury.

10 Aug 2012

Studies report on therapeutic efficacy of stem cell transplantation in animal models of ALS, SCI

Two studies published in a recent issue of Cell Medicine report on the therapeutic efficacy of stem cell transplantation in animal models of amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI).

20 Jul 2012

Psoriasis TNF-α therapeutic effects mediated by MSC antioxidant reduction

The therapeutic effects of tumor necrosis factor-α inhibitors in psoriasis occur through a reduction in the antioxidant response of mesenchymal stem cells, suggest study findings.

15 Jun 2012

Higher quality bone from stem cells

UCLA stem cell scientists purified a subset of stem cells found in fat tissue and made from them bone that was formed faster and was of higher quality than bone grown using traditional methods, a finding that may one day eliminate the need for painful bone grafts that use material taken from the patient during invasive procedures.

11 Jun 2012

Omentum appears to play an important role in regulating the immune system

A fatty membrane in the belly called the omentum has until recently been considered somewhat like the appendix -- it didn't seem to serve much purpose. But Loyola University Chicago Stritch School of Medicine researchers have found that the omentum appears to play an important role in regulating the immune system.

7 Jun 2012

FDA approves Arteriocyte’s ACD-A for use with Magellan system

Arteriocyte Medical Systems, Inc. announced today approval by the U.S. Food and Drug Administration (FDA) to manufacture and distribute the Arteriocyte Medical Systems brand of Anticoagulant Citrate Dextrose Solution, USP (ACD-A) for use with its Magellan Platelet Separation System.

5 Jun 2012

Special surface allows adult-derived stem cells to thrive and transform into multiple cell types

University of Michigan researchers have proven that a special surface, free of biological contaminants, allows adult-derived stem cells to thrive and transform into multiple cell types. Their success brings stem cell therapies another step closer.

25 May 2012

Regenerative medicine researchers explore innovative ways to treat childhood conditions

About 3 percent of the babies born in the United States have a birth defect. Children without a birth defect are also susceptible to injury or disease. At The University of Texas Health Science Center at Houston (UTHealth), regenerative medicine researchers are exploring innovative ways to treat these conditions.

21 May 2012

Growth promoting substance in human mesenchymal stem cells spurs restoration of nerves

A substance in human mesenchymal stem cells that promotes growth appears to spur restoration of nerves and their function in rodent models of multiple sclerosis (MS), researchers at Case Western Reserve University School of Medicine have found.

21 May 2012

Scientists show positive results with human MSCs in animal models of MS

The Myelin Repair Foundation (MRF) today announced the results of a new peer-reviewed research study published in Nature Neuroscience that demonstrates functional improvement in immune response modulation and myelin repair with factors derived from mesenchymal stem cell (MSC) treatment in animal models of multiple sclerosis.

21 May 2012

Breast cancer cell surface protein blows cover of potent tumor-generating cells

Breast cancer stem cells wear a cell surface protein that is part nametag and part bull's eye, identifying them as potent tumor-generating cells and flagging their vulnerability to a drug, researchers at The University of Texas MD Anderson Cancer Center report online in Journal of Clinical Investigation.

17 May 2012

Osiris Therapeutics first quarter total revenues decrease to $4.6M

Osiris Therapeutics, Inc., the leading stem cell company focused on developing and commercializing products to treat medical conditions in inflammatory, cardiovascular, orthopedic, and wound healing markets, announced today its results for the first quarter ended March 31, 2012.

11 May 2012

Study explores resilin-like materials for vocal fold disorders

A one-inch long grasshopper can leap a distance of about 20 inches. Cicadas can produce sound at about the same frequency as radio waves. Fleas measuring only millimeters can jump an astonishing 100 times their height in microseconds. How do they do it? They make use of a naturally occurring protein called resilin.

27 Apr 2012

Study: hUC-MSCs reduce inflammation that causes colitis

When laboratory mice were modeled with colitis and treated with human umbilical cord-derived mesenchymal cells, the cells homed in on the inflamed colon and effectively ameliorated colitis, reported a study published in a recent issue of Cell Transplantation.

24 Apr 2012

Nanoscale films promote bone growth

Every year, more than a million Americans receive an artificial hip or knee prosthesis. Such implants are designed to last many years, but in about 17 percent of patients who receive a total joint replacement, the implant eventually loosens and has to be replaced early, which can cause dangerous complications for elderly patients.

20 Apr 2012

FDA grants IDE approval for Arteriocyte's Magellan MAR01 Phase I Compartment Syndrome clinical trial

Arteriocyte, a leading biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts announced today approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial using its Magellan MAR01 technology in the treatment of Compartment Syndrome.

7 Apr 2012

Minimally invasive treatments could target ‘hunger hormone’

A minimally invasive treatment may target hunger at its source, another uses X-ray visible embolic beads to block arteries to the stomach and suppress hunger and a third explores the use of stem cells to repair vertebral disc degeneration. Initial results from all these studies were reported at the Society of Interventional Radiology's 37th Annual Scientific Meeting in San Francisco, Calif.

26 Mar 2012

Bone-marrow derived MSCs may reduce acute rejection rates in kidney recipients

Among patients with end-stage renal disease undergoing living-related kidney transplants, the use of bone-marrow derived mesenchymal (cells that can differentiate into a variety of cell types) stem cells instead of antibody induction therapy resulted in a lower incidence of acute rejection, decreased risk of opportunistic infection, and better estimated kidney function at 1 year, according to a study in the March 21 issue of JAMA.

21 Mar 2012

OHRI, uOttawa to lead first stem cell therapy trial for septic shock

A team of researchers from the Ottawa Hospital Research Institute (OHRI) and the University of Ottawa (uOttawa) has been awarded $367,000 from the Canadian Institutes of Health Research (CIHR) and $75,000 from the Stem Cell Network to lead the first clinical trial in the world of a stem cell therapy for septic shock.

16 Mar 2012